Cancer patients treated with the highly targeted supportive oligonucleotide therapy (SOT) showed benefits in 77% of cases, RGCC scientists have found. A new paper published in the in vivo journal finds evidence that SOTs effectively target and kill cancer cells on their own or in tandem with other therapies. Supportive oligonucleotide therapy is an advanced, […]
Mutations in BRCA1 and BRCA2 genes increase the risk of breast cancer but may also cause prostate and pancreatic cancers in men, Cambridge University scientists have discovered. After studying the medical history of thousands of families, the team found that 27% of men who carry a BRCA 2 mutation will develop prostate cancer, and those […]
Scientists worldwide are doing incredible things to improve the diagnosis and treatment of all forms of cancer. New approaches such as targeted immunotherapies are opening up new avenues for cancer treatment that prove highly effective. At RGCC, we’ve pioneered the use of personalised genetic testing for cancer diagnosis, and others are listening with the NHS […]
We are delighted to announce the launch of a brand-new branch office dedicated to serving the needs of RGCC Network doctors in North America. RGCC International – North America has been launched in response to a period of sustained and exponential growth in this region. The team will continue to deliver excellent customer service to […]
An advanced cancer therapy developed by RGCC scientists has been categorised as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA). Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Due to enter clinical trials […]
Activating protein p53 can boost a patient’s immune response against cancerous tumours, researchers at Sweden’s Karolinska Institutet have discovered. Using a commercially available substance known as ALRN-6924, the team successfully generated an anti-tumour immune response. The finding improves our understanding of the crucial role p53 plays in tumour development. In the future, it could help […]
RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]
RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities. Genistein is a naturally occurring […]
Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]
As the world tries to cope with the rise in cases of covid-19 during the coronavirus pandemic, drug companies are racing to develop treatments that could reduce the number of deaths from the illness. This includes the specialist medical genetic testing company RGCC, which has turned its expertise and technology in the diagnosis and treatment […]
We are happy to announce that we contributed to iGem Thessaloniki team’s won of the top prize in the international iGEM Synthetic Biology competition 2019, organized by MIT University in Boston. The project is called “POSEIDON” and it is a toolkit for the examination of DNA-Protein interactions. IGem team of Thessaloniki deploys the first DNA […]
In as little as two weeks, patients and clinicians can gain access to a next-generation genetic test provided by RGCC that can analyse the sequence of both DNA and RNA. The RGCC CAMBISeq® (Cancer Analysis, Mutational Burden and Instability Sequencing) test sequences DNA and RNA – the nucleic acids that carry genomic sequence information and […]
